The Ensign Group Q3 Earnings Call - ENSIGN GROUP INC

Financial Performance:

• Reported GAAP diluted EPS of $1.76 (up 23.9%) and Adjusted diluted EPS of $2.03 (up 23.8%) for Q3.
• Consolidated GAAP and adjusted revenue were $1.48 billion, a 14.5% decrease year-over-year, primarily attributed to timing of revenue recognition for newly acquired turnaround facilities not yet contributing full revenue.
• GAAP net income reached $104.3 million (up 24.4%); Adjusted net income was $120.5 million (up 24.9%).
• Same-store occupancy stood at 84.1%, with transitioning occupancy at 86.1%; same-store skilled mix revenue grew 10.7% and skilled days grew 7.2%.
• Cash position remains strong with $337.6 million in cash equivalents and $512.3 million in operating cash flow for the nine months ended September 30.
• Net debt-to-EBITDA ratio is approximately 2.0x, maintaining low leverage despite $675 million in capital deployment for growth.
• Available liquidity includes $730 million under the line of credit plus cash on hand, totaling over $1 billion in dry powder.

Guidance and Future Outlook:

• Raised full-year 2026 adjusted EPS guidance to a range of $7.94–$8.02 per share (previously $7.75–$7.85), representing a 21.5% increase over 2025.
• Raised full-year 2026 revenue guidance lower end to $5.89 billion, maintaining the upper end at $5.92 billion.
• 2026 EPS guidance midpoint implies 45.1% growth over 2024; 2025 share count assumption is approx. 59.5 million with a 25% tax rate.
• Management expresses high confidence in sustained growth through 2027, driven by core business strength and integration of acquisitions.
• Outlook assumes continued occupancy expansion (same-store at 84%) and skilled mix elevation in Q4, a historically strong quarter.
• Factors influencing guidance include reimbursement rates, state budget changes, seasonality, and the ramp-up timeline of new acquisitions.

Business Segments and Product Lines:

• Standard Bear Healthcare REIT: Added 8 assets (3 previously leased, now owned); portfolio now comprises 183 properties (146 leased to affiliates, 37 to third parties). Generated $47.7M rental revenue ($42.1M from affiliates) and $27.3M FFO for the quarter.
• Acquisitions: Closed 22 new operations (19 leased, 3 real estate) during the quarter, adding 2,373 skilled nursing beds and 113 independent living beds.
• Geographic Expansion: Successfully entered Florida (9 facilities) and expanded footprint in Colorado (7 facilities) and Washington (4 facilities).
• Clinical Model: "One Clinical" model integrates therapy and nursing, resulting in 21% higher CMS quality measures than state averages and 30% better functional improvement for short-stay residents.
• Leadership Pipeline: Approximately 52 Assistant to CEO (AIT) candidates in training; average of 122 operations sourced and closed since 2024.

Market and Competitive Landscape:

• Ensign achieved CMS high-performing facility designations for 12% of eligible operations, significantly outperforming the national average.
• Occupancy growth is being driven by superior clinical outcomes, which foster trust among hospitals and managed care organizations, leading to increased referrals for complex cases.
• Skilled payer mix grew across all categories (Medicare up 11.1%, managed care up 9.1% for same-store), indicating successful capture of higher-acuity patients.
• Market dynamics show a steady flow of opportunities from non-profits divesting assets, REITs seeking portfolio restructuring, and landlord transitions.
• Differentiator includes a decentralized transition model that utilizes local cluster leadership to rapidly integrate acquisitions, contrasting with centralized approaches.

Risks and Challenges:

• Acquisition Integration: Recent acquisitions in Florida and Texas are turnaround properties with significant clinical, operational, and physical plant challenges; management expects a 12-24 month ramp-up period before financial contribution.
• Litigation Environment: Florida's historically high litigation risk was a primary barrier to entry, though the environment has stabilized recently.
• Labor Market: Specific challenges noted in high-cost areas like Bainbridge Island, WA, regarding workforce retention and commuting; however, RN retention remains 11% better than state averages.
• Regulatory: Navigating varying state regulatory environments, particularly in difficult survey states like Washington.
• Capital Allocation: Balancing aggressive growth (M&A) with maintaining a healthy balance sheet and liquidity position.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing a "relentless commitment to excellence" and a culture-driven approach (CAPLICO values).
• Management frames growth not just as financial expansion but as a mission to "dignify post-acute care" through clinical superiority.
• Strong emphasis on the causal link between clinical outcomes (lower readmissions, better quality scores) and financial performance (occupancy, skilled mix).
• CEO and CFO highlighted that current growth pace (50-60 acquisitions annually) is sustainable due to a robust leadership pipeline and disciplined balance sheet.
• Leadership expressed pride in the stability of long-tenured local executives (e.g., 19-year ED in Tennessee) as a key differentiator for successful transitions.

Analyst Questions and Answers:

• Florida Market Entry: Analyst asked about challenges; Management cited the historical litigation risk as the main hurdle, now mitigated by stable rates and experienced local leadership. Confirmed ability to leverage existing payer relationships to accelerate high-acuity admissions.
• Guidance vs. Acquisition Ramp: Analyst queried how core business supports guidance despite underperforming new deals; Management clarified that core operations are strong (84% occupancy) and new Florida/Texas deals are expected to take 1+ years to accrete.
• Skilled Mix Sustainability: Analyst asked about sustaining high skilled mix levels; Management attributed this to consistent clinical outcomes building trust with payers, rather than just demographic tailwinds.
• M&A Pace and Pipeline: Analyst inquired about future deal flow; Management stated they are opportunistic, not growth-target constrained, and have a strong pipeline including larger portfolios and high-quality physical plants. Confirmed ability to execute 50-60 deals annually.
• Real Estate Buyouts: Analyst asked about converting leases to ownership; Management confirmed this is an ongoing strategy, citing recent acquisitions of facilities leased from public REITs and family-owned operators as the lease terms mature.
• AI and Technology: Inquired about AI initiatives; Management highlighted the rollout of documentation support, coding compliance tools, and clinical decision support systems developed in partnership with EMR providers.

Other Key Points:

• The company pays a quarterly cash dividend of $0.065 per share, marking 23 consecutive years of annual dividend increases.
• Enzyme Group operates as a holding company with independent subsidiaries handling operations, supported by a "Service Center" for shared services (HR, IT, Legal).
• 122 operations have been acquired and transitioned since 2024, with many already performing at or above expectations.
• Management emphasized that their "One Clinical" model breaks down silos between therapy and nursing, a key driver of their 30% better functional improvement rates compared to peers.
• The company holds 189 assets, 165 of which are debt-free, providing significant operational flexibility.